Rockwell Medical (NASDAQ:RMTI) Earns Buy Rating from Analysts at Rodman & Renshaw

Rodman & Renshaw assumed coverage on shares of Rockwell Medical (NASDAQ:RMTI) in a research note published on Thursday, MarketBeat reports. The firm issued a buy rating and a $5.00 price objective on the stock.

Other analysts have also recently issued reports about the company. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Rockwell Medical in a research report on Wednesday, September 11th. StockNews.com raised Rockwell Medical from a “hold” rating to a “buy” rating in a research note on Wednesday.

Rockwell Medical Stock Down 5.4 %

RMTI opened at $2.36 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.60 and a current ratio of 2.41. Rockwell Medical has a 1 year low of $1.16 and a 1 year high of $5.15. The stock’s 50 day simple moving average is $3.68 and its 200-day simple moving average is $2.61.

Institutional Trading of Rockwell Medical

Institutional investors have recently bought and sold shares of the stock. Concurrent Investment Advisors LLC acquired a new position in Rockwell Medical in the third quarter worth $40,000. Verus Capital Partners LLC acquired a new position in Rockwell Medical in the third quarter worth $51,000. Barclays PLC acquired a new position in Rockwell Medical in the third quarter worth $90,000. Beacon Financial Advisory LLC acquired a new position in Rockwell Medical in the third quarter worth $98,000. Finally, XTX Topco Ltd boosted its stake in Rockwell Medical by 45.7% in the third quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock worth $113,000 after purchasing an additional 8,922 shares in the last quarter. Institutional investors and hedge funds own 23.31% of the company’s stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.